Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) — Capital Reinvestment Ratio
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has a Capital Reinvestment Ratio of 0.19x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥110.78 Million) in capital expenditures (CN¥21.06 Million). See 600329 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Capital Reinvestment Ratio (2001–2024)
This chart tracks Tianjin Zhongxin Pharmaceutical Group Corp Ltd's Capital Reinvestment Ratio across 22 annual periods. Check 600329 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2001–2024)
Year-by-year Capital Reinvestment Ratio for Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 2001 to 2024. For live market cap and broader valuation context, see how much is Tianjin Zhongxin Pharmaceutical Group Co worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.13x | CN¥924.67 Million | CN¥117.81 Million | ▼ -37.8% |
| 2023 | 0.20x | CN¥688.49 Million | CN¥140.93 Million | ▲ +28.5% |
| 2022 | 0.16x | CN¥677.25 Million | CN¥107.90 Million | ▼ -13.5% |
| 2021 | 0.18x | CN¥852.40 Million | CN¥156.95 Million | ▼ -34.6% |
| 2020 | 0.28x | CN¥671.42 Million | CN¥189.16 Million | ▼ -32.1% |
| 2019 | 0.41x | CN¥495.49 Million | CN¥205.61 Million | ▼ -17.4% |
| 2018 | 0.50x | CN¥350.14 Million | CN¥175.81 Million | ▲ +81.4% |
| 2016 | 0.28x | CN¥419.90 Million | CN¥116.20 Million | ▲ +7.7% |
| 2015 | 0.26x | CN¥360.58 Million | CN¥92.64 Million | ▲ +5.1% |
| 2014 | 0.24x | CN¥286.85 Million | CN¥70.15 Million | ▼ -27.9% |
| 2013 | 0.34x | CN¥213.44 Million | CN¥72.42 Million | ▼ -82.9% |
| 2012 | 1.98x | CN¥20.81 Million | CN¥41.18 Million | ▲ +699.8% |
| 2011 | 0.25x | CN¥173.88 Million | CN¥43.02 Million | ▼ -50.0% |
| 2010 | 0.49x | CN¥139.04 Million | CN¥68.79 Million | ▼ -52.4% |
| 2009 | 1.04x | CN¥83.41 Million | CN¥86.74 Million | ▲ +322.2% |
| 2008 | 0.25x | CN¥155.77 Million | CN¥38.36 Million | ▼ -90.8% |
| 2007 | 2.67x | CN¥20.13 Million | CN¥53.74 Million | ▲ +366.7% |
| 2005 | 0.57x | CN¥261.91 Million | CN¥149.80 Million | ▼ -97.6% |
| 2004 | 24.04x | CN¥10.50 Million | CN¥252.31 Million | ▲ +212.4% |
| 2003 | 7.70x | CN¥76.57 Million | CN¥589.20 Million | ▲ +700.3% |
| 2002 | 0.96x | CN¥187.60 Million | CN¥180.40 Million | ▲ +13.2% |
| 2001 | 0.85x | CN¥157.73 Million | CN¥133.95 Million | — |